간행물

생화학분자생물학회입니다.


EMM

Th17 cell pathogenicity in autoimmune disease

  • 작성자

    Maria Ciofani, PhD
  • 작성일자

    2025-12-24
  • 조회수

    150
Name: Maria Ciofani, PhD ( maria.ciofani@duke.edu )
2021-present Associate Professor of Molecular Genetics and Microbiology, Duke University School of Medicine, Durham, NC, USA
2020-present Associate Professor of Integrative Immunobiology, Duke University School of Medicine, Durham, NC, USA
2013-2020 Assistant Professor of Immunology, Duke University School of Medicine, Durham, NC, USA
2007-2013 Postdoctoral Fellow, Dept of Pathology, New York University, NY, USA
2000-2007 PhD, Dept of Immunology, University of Toronto, Canada

Th17 cell pathogenicity in autoimmune disease

T helper 17 (Th17) cells have been implicated in numerous inflammatory autoimmune diseases. Clinical benefits from targeting Th17 cell-related cytokines, such as IL-17 and IL-23, highlight how knowledge of Th17 cell development and effector function can be translated into treatments for inflammatory disease. Here we discuss the pathogenic roles of Th17 cells in autoimmune diseases such as multiple sclerosis, inflammatory bowel disease and psoriasis, with emphasis on the cytokines, transcriptional regulators and metabolites that influence Th17 cell differentiation and pathogenicity. Moreover, we address how intestinal environments and physiological responses affect Th17 cells in autoimmune diseases. We also examine current and emerging therapeutic strategies aimed at regulating Th17 cell-driven inflammation to mitigate autoimmune diseases.


Exp Mol Med. 2025 Sep;57(9):1913-1927. doi: 10.1038/s12276-025-01535-9.
https://pubmed.ncbi.nlm.nih.gov/40887501/